Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers

MeSH terms

• Anticarcinogenic Agents / therapeutic use*
• Biomarkers, Tumor / analysis*
• Clinical Trials, Phase II as Topic
• Drug Approval
• Drug Design
• Humans
• Neoplasms / pathology
• Neoplasms / prevention & control*
• Neoplastic Processes
• Phenotype
• Precancerous Conditions / prevention & control*
• Predictive Value of Tests
• Reproducibility of Results